Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. - Wikidata - awgldk - TriplyDB

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q37750734

about

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisal Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.Cetuximab in the treatment of squamous cell carcinoma of the head and neck.Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal.Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal.Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.Inventory of economic evaluation of head and neck oncology from the German perspective.Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer.

P2860

Q33400612-0F0DA2D8-9096-4813-A638-8DA6056C58A6 Q34573847-77D71D5B-36EF-474B-9995-6273527A36F4 Q36844535-F6E8B662-53B3-4F6C-ACEE-50A6C6AC586F Q37866779-A5709EB0-F95E-41F9-B992-577946C059C8 Q37919866-B0FBE7EB-D174-4E44-AAC6-24EC482BCE39 Q37941769-D3B7FFFA-CA10-443E-B33A-759338679963 Q37963977-1A5BA589-CCD0-465C-B308-4B40926B35DB Q37970113-7D312A4E-D954-4C6A-87FA-32C7D1037ED3 Q37979273-0F75FAFD-B3A0-4045-95E5-CD011C677177 Q38040848-AF383C50-1604-446A-9153-028A9BFC8A4A Q38051449-7FEBBF6F-269E-461F-8908-3E81C53D3415 Q38074913-F643CCF9-1524-4EEF-A8DA-97B3C060A7FE Q38076077-5321D663-6BC8-49E6-AAFE-18BDD9E9E40B Q38078288-B2683499-B1D6-4708-B392-FDB4CF95A7D6 Q38091324-3A96D0A1-F555-4B62-A81B-AD518B13FCA0 Q38097338-2A50EAEA-A92C-4363-8B82-C89A7D689485 Q38098104-BAB0D9D8-B60F-4856-A92E-06EF98FE8BB2 Q38098483-65162D6A-5354-4204-8586-BD74B2B24CAB Q38098484-097B1312-FDD4-4B55-B270-B4C0CEA50FC1 Q38101892-0834D3DA-82CB-4EF0-9CED-461560F25319 Q38133381-F5EE7577-0A58-4516-B781-7DDE4B42E3A1 Q38149091-1A74ABD0-A681-4266-B0D8-7BF784D26C77 Q38176769-0C23D6F9-1815-4FDD-97F0-1B1EAC4337BB Q51020348-7A204666-F150-4877-9F7B-C1D4EEFC381D

P2860

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

http://www.wikidata.org/entity/Q37750734

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cetuximab for recurrent and/or ...... E single technology appraisal.

@en

Cetuximab for recurrent and/or ...... E single technology appraisal.

@nl

type

label

Cetuximab for recurrent and/or ...... E single technology appraisal.

@en

Cetuximab for recurrent and/or ...... E single technology appraisal.

@nl

prefLabel

Cetuximab for recurrent and/or ...... E single technology appraisal.

@en

Cetuximab for recurrent and/or ...... E single technology appraisal.

@nl

P1433

Q37750734-B0FC2711-1988-495B-B5A4-B5AB623F6AFD

P1476

Q37750734-3D6F8DF5-80B4-4E31-8A1D-EC16DD99BB24

P2093

Q37750734-3551E9B1-3D67-4CCD-87FC-C698413383E8

Q37750734-6982A7D4-DED1-429E-997B-860760DE0049

Q37750734-75F48A8C-BC11-42D6-A242-2D4096E8481F

Q37750734-84BEA270-4518-4791-BC2D-C5E318E2828A

Q37750734-89611520-0384-47A1-B20A-EFB96FAB8249

Q37750734-8BB95D55-99EF-44A5-8CD6-EF14C3EA1610

Q37750734-E5776BED-E2D6-4F8A-B78E-DC4BE47288F4

Q37750734-F029D384-D79C-44CB-B22D-6FBF6079A444

Q37750734-FD622093-41AC-452A-8C81-0B79527738C7

P2888

Q37750734-128F8536-0201-4016-BC64-5F4F6623F830

P304

Q37750734-285CA844-7BAD-4A02-9A9A-8BB6E1189380

P31

Q37750734-3BC7F0F7-6BB5-45E6-BFE2-066B39BC2D84

P356

Q37750734-AF10B3CD-943C-41B2-9C17-9A696B667681

P433

Q37750734-ED03FFFF-E135-4C9B-8376-325B59E90085

P478

Q37750734-BF2246F1-B3FB-4E57-9253-AD8E121F50CC

P577

Q37750734-D29EC0C4-9F1E-4E2F-91B9-03324907EF8A

P6179

Q37750734-73335A4A-BA40-4CDD-BAD1-23DFB0718076

P698

Q37750734-F3DBE6AB-5092-4C5B-8303-DAEFBCA406D9

P921

Q37750734-38D0FAE3-9304-4AC1-8ED7-2FDEE67513DF

P356

11532220-000000000-00000

P1433

PharmacoEconomics

P1476

Cetuximab for recurrent and/or ...... E single technology appraisal.

@en

P2093

Adrian Bagust

http://www.w3.org/2001/XMLSchema#string

Angela Boland

http://www.w3.org/2001/XMLSchema#string

Christine Proudlove

http://www.w3.org/2001/XMLSchema#string

Claire McLeod

http://www.w3.org/2001/XMLSchema#string

Janette Greenhalgh

http://www.w3.org/2001/XMLSchema#string

Nigel Fleeman

http://www.w3.org/2001/XMLSchema#string

Richard Shaw

http://www.w3.org/2001/XMLSchema#string

Rumona Dickson

http://www.w3.org/2001/XMLSchema#string

Yenal Dundar

http://www.w3.org/2001/XMLSchema#string

P2888

11532220-000000000-00000

P304

439-448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11532220-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1016368185

http://www.w3.org/2001/XMLSchema#string

P698

20465313

http://www.w3.org/2001/XMLSchema#string

P921